Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
RedHill Biopharma ( (RDHL) ) just unveiled an announcement.
On February 25, 2026, RedHill Biopharma announced the start of the full sales and operational launch of Talicia in the U.S. under a joint commercialization agreement with Cumberland Pharmaceuticals, executed via their jointly controlled entity Talicia Holdings Inc. THI, owned 70% by RedHill and 30% by Cumberland, will manage launch and ongoing commercial activities to accelerate Talicia’s market penetration and expand its reach among gastroenterologists.
Talicia is the leading branded H. pylori therapy prescribed by U.S. gastroenterologists and the only FDA-approved all-in-one, low-dose rifabutin-based regimen designed to address rising antibiotic resistance, backed by U.S. market exclusivity and patent protection through 2042. RedHill is also pursuing new market entries for Talicia in the U.K. and the Middle East and seeking additional ex-U.S. licensing revenue, positioning the product for broader global adoption in a large and growing H. pylori treatment market where eradication failure remains a significant clinical challenge.
The most recent analyst rating on (RDHL) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on RedHill Biopharma stock, see the RDHL Stock Forecast page.
Spark’s Take on RDHL Stock
According to Spark, TipRanks’ AI Analyst, RDHL is a Neutral.
Score is held down primarily by weak financial performance (ongoing losses, negative equity, and negative operating/free cash flow). Technicals provide a partial offset with improving short-term trend and momentum, but longer-term trend and MACD remain unsupportive. Valuation impact is neutral due to missing P/E and dividend yield.
To see Spark’s full report on RDHL stock, click here.
More about RedHill Biopharma
RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused primarily on the U.S. development and commercialization of drugs for gastrointestinal diseases, infectious diseases and oncology. The company currently promotes Talicia, an FDA-approved treatment for Helicobacter pylori infection in adults, and is advancing several late-stage clinical programs across inflammatory, infectious and oncologic indications.
Average Trading Volume: 493,981
Technical Sentiment Signal: Sell
Current Market Cap: $5.04M
Find detailed analytics on RDHL stock on TipRanks’ Stock Analysis page.